175P Prosigna test for early breast cancer patients in real-life

Delphine Hequet, Roman Rouzier,Florence Lerebours,Emmanuelle Menet,Florence Dalenc,V. Nicolai,N. Hajjaji,Sandrine Lavau-Denes,V. Fermeaux, L. Texier,Anne Cayre,E. Charafe Jauffret,A. Boucrauta,Olivier Tredan, J. Lopez

ANNALS OF ONCOLOGY（2021）

引用 0|浏览4

暂无评分

摘要

Genomic tests are used as adjuvant chemotherapy decision support tool in HR + HER2- breast cancer (BC) patients. In France, the Health Authorities have recently advised indications for tests in case of intermediate risk of recurrence: pT1c-pT2 pN0-pN1mic grade 2 BC (the HA group). However, in routine practice, some tests were performed before and outside these indications. The aim of this study was to identify a population that benefits from performing a genomic test in real world setting.

查看译文

关键词

prosigna test,early breast cancer patients,breast cancer,real-life

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要